International Journal of Antimicrobial Agents
Volume 39, Issue 2 , Pages 105-114 , February 2012

Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options

References 

  1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538–582
  2. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11:868–873
  3. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42:692–699
  4. Oncul O, Keskin O, Acar HV, Kucukardali Y, Evrenkaya R, Atasoyu EM, et al. Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect. 2002;51:47–51
  5. Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, et al. An outbreak of multidrug-resistant Acinetobacter baumannii–calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis. 2007;44:1577–1584
  6. Coelho J, Woodford N, Turton J, Livermore DM. Multiresistant Acinetobacter in the UK: how big a threat?. J Hosp Infect. 2004;58:167–169
  7. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol. 2007;45:3352–3359
  8. Paton R, Miles RS, Hood J, Amyes SG, Miles RS, Amyes SG. ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents. 1993;2:81–87
  9. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis. 2001;7:319–322
  10. Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ, Docobo-Perez F, Smani Y, Fernandez-Reyes M, et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis. 2011;203:545–548
  11. Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009;65:188–191
  12. Park YK, Jung SI, Park KH, Cheong HS, Peck KR, Song JH, et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis. 2009;64:43–51
  13. Rolain JM, Roch A, Castanier M, Papazian L, Raoult D. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J Infect Dis. 2011;204:1146–1147
  14. López-Rojas R, Jiménez-Mejías ME, Lepe JA, Pachón J. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis. 2011;204:1147–1148
  15. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol. 2003;41:3542–3547
  16. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2006;2:e7
  17. Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E, et al. Comparative analysis of Acinetobacters: three genomes for three lifestyles. PLoS One. 2008;3:e1805
  18. Nigro SJ, Post V, Hall RM. The multiresistant Acinetobacter baumannii European clone I type strain RUH875 (A297) carries a genomic antibiotic resistance island AbaR21, plasmid pRAY and a cluster containing ISAba1–sul2-CR2–strB–strA. J Antimicrob Chemother. 2011;66:1928–1930
  19. Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, Jamison JJ, et al. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol. 2008;190:8053–8064
  20. Post V, White PA, Hall RM. Evolution of AbaR-type genomic resistance islands in multiply antibiotic-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:1162–1170
  21. Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen MJ, Turton JF, et al. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother. 2011;66:1499–1503
  22. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol. 1998;36:1938–1941
  23. McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of Acinetobacter infections: 1987–1996. Nosocomial Infections Surveillance System. Clin Infect Dis. 1999;29:1133–1137
  24. Berlau J, Aucken HM, Houang E, Pitt TL. Isolation of Acinetobacter spp. including A. baumannii from vegetables: implications for hospital-acquired infections. J Hosp Infect. 1999;42:201–204
  25. Berlau J, Aucken H, Malnick H, Pitt T. Distribution of Acinetobacter species on skin of healthy humans. Eur J Clin Microbiol Infect Dis. 1999;18:179–183
  26. Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol. 1997;35:2819–2825
  27. Dijkshoorn L, van Aken E, Shunburne L, van der Reijden TJ, Bernards AT, Nemec A, et al. Prevalence of Acinetobacter baumannii and other Acinetobacter spp. in faecal samples from non-hospitalised individuals. Clin Microbiol Infect. 2005;11:329–332
  28. Catalano M, Quelle LS, Jeric PE, Di Martino A, Maimone SM. Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases. J Hosp Infect. 1999;42:27–35
  29. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol. 1997;35:1394–1397
  30. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis. 2007;45:409–415
  31. Tao C, Kang M, Chen Z, Xie Y, Fan H, Qin L, et al. Microbiologic study of the pathogens isolated from wound culture among Wenchuan earthquake survivors. Diagn Microbiol Infect Dis. 2009;63:268–270
  32. La SB, Fournier PE, Brouqui P, Raoult D. Detection and culture of Bartonella quintana, Serratia marcescens, and Acinetobacter spp. from decontaminated human body lice. J Clin Microbiol. 2001;39:1707–1709
  33. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006;55:1619–1629
  34. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother. 2003;52:629–635
  35. Rodriguez-Martinez JM, Nordmann P, Ronco E, Poirel L. Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:3484–3488
  36. Mantengoli E, Rossolini GM. Tn5393d, a complex Tn5393 derivative carrying the PER-1 extended-spectrum β-lactamase gene and other resistance determinants. Antimicrob Agents Chemother. 2005;49:3289–3296
  37. Poirel L, Naas T, Nordmann P. Genetic support of extended-spectrum β-lactamases. Clin Microbiol Infect. 2008;14(Suppl. 1):75–81[Erratum in: Clin Microbiol Infect 2008;14(Suppl. 5):21–4]
  38. Naas T, Coignard B, Carbonne A, Blanckaert K, Bajolet O, Bernet C, et al. VEB-1 extended-spectrum β-lactamase-producing Acinetobacter baumannii, France. Emerg Infect Dis. 2006;12:1214–1222
  39. Naas T, Bogaerts P, Bauraing C, Degheldre Y, Glupczynski Y, Nordmann P. Emergence of PER and VEB extended-spectrum β-lactamases in Acinetobacter baumannii in Belgium. J Antimicrob Chemother. 2006;58:178–182
  40. Pasteran F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, et al. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother. 2006;50:3222–3224
  41. Jeong SH, Bae IK, Kwon SB, Lee K, Yong D, Woo GJ, et al. Investigation of a nosocomial outbreak of Acinetobacter baumannii producing PER-1 extended-spectrum β-lactamase in an intensive care unit. J Hosp Infect. 2005;59:242–248
  42. Litake GM, Ghole VS, Niphadkar KB, Joshi SG. PER-1-type extended-spectrum β-lactamase-producing Acinetobacter baumannii clinical isolates from India. Int J Antimicrob Agents. 2009;34:388–389
  43. Naas T, Kernbaum S, Allali S, Nordmann P. Multidrug-resistant Acinetobacter baumannii, Russia. Emerg Infect Dis. 2007;13:669–671
  44. Strateva T, Todorova A, Ouzounova-Raykova V, Mitov I. Emergence of a PER-1 extended-spectrum β-lactamase-producing Acinetobacter baumannii clinical isolate in Bulgaria. J Chemother. 2008;20:391–392
  45. Szabo D, Szentandrassy J, Juhasz Z, Katona K, Nagy K, Rokusz L. Imported PER-1 producing Pseudomonas aeruginosa, PER-1 producing Acinetobacter baumannii and VIM-2-producing Pseudomonas aeruginosa strains in Hungary. Ann Clin Microbiol Antimicrob. 2008;7:12
  46. Zhang JP, Zhu W, Tian SF, Chu YZ, Chen BY. Molecular characteristics and resistant mechanisms of imipenem-resistant Acinetobacter baumannii isolates in Shenyang, China. J Microbiol. 2010;48:689–694
  47. Bonnin RA, Potron A, Poirel L, Lecuyer H, Neri R, Nordmann P. PER-7, an extended spectrum β-lactamase with increased activity toward broad-spectrum cephalosporins in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:2424–2427
  48. Bonnin RA, Nordmann P, Potron A, Lecuyer H, Zahar JR, Poirel L. Carbapenem-hydrolyzing GES-type extended-spectrum β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:349–354
  49. Moubareck C, Bremont S, Conroy MC, Courvalin P, Lambert T. GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob Agents Chemother. 2009;53:3579–3581
  50. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:233–238
  51. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA β-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother. 2000;44:196–199
  52. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–836
  53. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother. 2010;54:24–38
  54. Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. J Antimicrob Chemother. 2010;65:2253–2254
  55. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries. 2009;3:335–341
  56. Kaase M, Nordmann P, Wichelhaus TA, Gatermann SG, Bonnin RA, Poirel L. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother. 2011;66:1260–1262
  57. Chen Y, Zhou Z, Jiang Y, Yu Y. Emergence of NDM-1-producing Acinetobacter baumannii in China. J Antimicrob Chemother. 2011;66:1255–1259
  58. Rolain JM, Parola P, Cornaglia G. New Delhi metallo-β-lactamase (NDM-1): towards a new pandemia?. Clin Microbiol Infect. 2010;16:1699–1701
  59. Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect. 2010;16:112–122
  60. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm?. Clin Microbiol Rev. 2005;18:306–325
  61. Kusradze I, Diene SM, Goderdzishvili M, Rolain JM. Molecular detection of OXA carbapenemase genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq and Georgia. Int J Antimicrob Agents. 2011;38:164–168
  62. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006;258:72–77
  63. Drissi M, Poirel L, Mugnier PD, Baba AZ, Nordmann P. Carbapenemase-producing Acinetobacter baumannii, Algeria. Eur J Clin Microbiol Infect Dis. 2010;29:1457–1458
  64. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2010;16:35–40
  65. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601
  66. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother. 2009;53:3628–3634
  67. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54:4971–4977
  68. Alhanout K, Brunel JM, Raoult D, Rolain JM. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis. J Antimicrob Chemother. 2009;64:810–814
  69. Alhanout K, Malesinki S, Vidal N, Peyrot V, Rolain JM, Brunel JM. New insights into the antibacterial mechanism of action of squalamine. J Antimicrob Chemother. 2010;65:1688–1693
  70. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. The insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55:3022–3024
  71. Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J Med Microbiol. 2007;56:165–171
  72. Rodloff AC, Leclercq R, Debbia EA, Canton R, Oppenheim BA, Dowzicky MJ. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the Tigecycline Evaluation and Surveillance Trial. Clin Microbiol Infect. 2008;14:307–314
  73. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents. 2008;32:29–32
  74. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977–2000. Infect Control Hosp Epidemiol. 2003;24:284–295
  75. Da Silva G, Dijkshoorn L, van der Reijden T, van Strijen B, Duarte A. Identification of widespread, closely related Acinetobacter baumannii isolates in Portugal as a subgroup of European clone II. Clin Microbiol Infect. 2007;13:190–195
  76. Kresken M, Becker K, Seifert H, Leitner E, Körber-Irrgang B, von Eiff C, et al. Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany. Eur J Clin Microbiol Infect Dis. 2011;30:1095–1103
  77. Oteo J, García-Estébanez C, Migueláñez S, Campos J, Martí S, Vila J, et al. Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain. J Infect. 2007;55:260–266
  78. Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002–2004. Diagn Microbiol Infect Dis. 2005;53:265–271
  79. Nordmann P, Picazo JJ, Mutters R, Korten V, Quintana A, Laeuffer JM, et al. Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother. 2011;66:1070–1078
  80. Van Looveren M, Goossens H ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect. 2004;10:684–704
  81. D’Arezzo S, Principe L, Capone A, Petrosillo N, Petrucca A, Visca P. Changing carbapenemase gene pattern in an epidemic multidrug-resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy. J Antimicrob Chemother. 2011;66:54–61
  82. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 2008;13:pii: 19045
  83. Gur D, Korten V, Unal S, Deshpande LM, Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol. 2008;57:1529–1532
  84. Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008;27:607–612
  85. Bogaerts P, Naas T, Wybo I, Bauraing C, Soetens O, Pierard D, et al. Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium. J Clin Microbiol. 2006;44:4189–4192
  86. Zarrilli R, Casillo R, Di Popolo A, Tripodi MF, Bagattini M, Cuccurullo S, et al. Molecular epidemiology of a clonal outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Italy. Clin Microbiol Infect. 2007;13:481–489
  87. Luna CM, Aruj PK. Nosocomial Acinetobacter pneumonia. Respirology. 2007;12:787–791
  88. Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis. 2005;41:848–854
  89. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317
  90. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case–control studies. Crit Care. 2006;10:R48
  91. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis. 2006;43:389–390
  92. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148–165
  93. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333–1341
  94. Stein A, Raoult D. Colistin: an antimicrobial for the 21st century?. Clin Infect Dis. 2002;35:901–902
  95. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother. 2004;48:1586–1592
  96. Brauers J, Frank U, Kresken M, Rodloff AC, Seifert H. Activities of various β-lactams and β-lactam/β-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clin Microbiol Infect. 2005;11:24–30
  97. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis. 2010;51:79–84
  98. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother. 1998;42:793–802
  99. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin–sulbactam and imipenem–cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002;34:1425–1430
  100. Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem–cilastatin or ampicillin–sulbactam. Pharmacotherapy. 2001;21:142–148
  101. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M, Porath A, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin–sulbactam treatment. J Hosp Infect. 2003;54:32–38
  102. Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med. 2003;2:321–332
  103. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med. 2003;31:2478–2482
  104. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115–121
  105. Enoch DA, Summers C, Brown NM, Moore L, Gillham MI, Burnstein RM, et al. Investigation and management of an outbreak of multidrug-carbapenem-resistant Acinetobacter baumannii in Cambridge, UK. J Hosp Infect. 2008;70:109–118
  106. Livermore DM, Hill RL, Thomson H, Charlett A, Turton JF, Pike R, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents. 2010;35:19–24
  107. Consales G, Gramigni E, Zamidei L, Bettocchi D, De Gaudio AR. A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational strategies. J Crit Care. 2011;26:453–459
  108. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007;59:128–131
  109. Diene SM, Bruder N, Raoult D, Rolain JM. Real-time PCR allows detection of the New Delhi metallo-β-lactamase (NDM-1)-encoding gene in France. Int J Antimicrob Agents. 2011;37:544–546
  110. Espinal P, Fugazza G, López Y, Kasma M, Lerman Y, Malhotra-Kumar S, et al. Dissemination of an NDM-2-producing Acinetobacter baumannii clone in an Israeli rehabilitation center. Antimicrob Agents Chemother. 2011;55:5396–5398
  111. Goic-Barisic I, Towner KJ, Kovacic A, Sisko-Kraljevic K, Tonkic M, Novak A, et al. Outbreak in Croatia caused by a new carbapenem-resistant clone of Acinetobacter baumannii producing OXA-72 carbapenemase. J Hosp Infect. 2011;77:368–369
  112. Mendes RE, Spanu T, Deshpande L, Castanheira M, Jones RN, Fadda G. Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. Clin Microbiol Infect. 2009;15:588–592
  113. Culebras E, Gonzalez-Romo F, Head J, Gomez M, Morales G, Picazo JJ. Outbreak of Acinetobacter baumannii producing OXA-66 in a Spanish hospital: epidemiology and study of patient movements. Microb Drug Resist. 2010;16:309–315
  114. Kohlenberg A, Brummer S, Higgins PG, Sohr D, Piening BC, de Grahl C, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. J Med Microbiol. 2009;58:1499–1507
  115. Tsakris A, Ikonomidis A, Poulou A, Spanakis N, Vrizas D, Diomidous M, et al. Clusters of imipenem-resistant Acinetobacter baumannii clones producing different carbapenemases in an intensive care unit. Clin Microbiol Infect. 2008;14:588–594
  116. Meric M, Kasap M, Gacar G, Budak F, Dundar D, Kolayli F, et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital in Turkey. FEMS Microbiol Lett. 2008;282:214–218
  117. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol. 2005;43:4826–4829
  118. Poirel L, Lebessi E, Heritier C, Patsoura A, Foustoukou M, Nordmann P. Nosocomial spread of OXA-58-positive carbapenem-resistant Acinetobacter baumannii isolates in a paediatric hospital in Greece. Clin Microbiol Infect. 2006;12:1138–1141
  119. Heritier C, Dubouix A, Poirel L, Marty N, Nordmann P. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J Antimicrob Chemother. 2005;55:115–118
  120. Pérez-Pedrero MJ, Sánchez-Casado M, Rodríguez-Villar S. Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients. Med Intensiva. 2011;35:226–231[in Spanish]
  121. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case–control study. Clin Infect Dis. 2010;51:1238–1244
  122. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003;7:R78–R83

PII: S0924-8579(11)00422-5

doi: 10.1016/j.ijantimicag.2011.10.004

International Journal of Antimicrobial Agents
Volume 39, Issue 2 , Pages 105-114 , February 2012

Article Tools

* Image Usage & Resolution